A closer look into blood group discrepancy arising due to an underlying malignancy

Subramaniyan, Rajeswari; Gaspar, Balan Louis

doi:10.1016/j.bjhh.2016.04.007

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, Subramanian et al concluded that rarely patients with carcinoma and lymphoma can develop excess serum blood group substances, able to deactivate the typing antisera. 28,29 Since the pretransplant antibody removal and standard immunosuppressive drug medicine as the only additional pretreatment was postulated to be insufficient when using group A1 and B donors, 30 the use of donor plasma able to inhibit agglutination and haemolysis of erythrocytes (as was revealed in the present study) might be important in ABO incompatible transplantation. Whether the use of the plasma of the donors with type II-III of ABO discrepancy will increase the long-term graft survival in ABO incompatible transplantation remains to be shown.…”

Section: Discussionmentioning

confidence: 67%

“…Blood group antigens are known as an expression of human individuality and in pathological conditions a reduction of the expression of group A and B antigens is accompanied by an increase of the expression of precursor molecules. 14,28,29 Type III discrepancies were found in persons with modification of blood group type: a person of O blood group with anti-A (1:8 titre) and anti-B antibodies (1:4 titre) after allogeneic group AB transplantation for juvenile myelomonocytic leukaemia showed modification of blood group type: the forward typing demonstrated conversion to AB blood group (anti-A and anti-B reagents showed weak mixed-field agglutination). 17,30 Type III discrepancy was observed in persons with Hodgkin lymphoma, cord blood and plasma exchange with dextran or polyvinyl pyrrolidone.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Resolving discrepancies in forward and reverse ABO blood group typing

Grigorovich,

Olexiyovich,

Solomonivna

et al. 2023

Scripta Medica

View full text Add to dashboard Cite

Background/Aim: There is a need of investigation of high frequency of the cases of ABO discrepancy revealed by forward and reverse typing. The aim of the study was to reveal optimal methods for detection of weak subgroups of group A and B antigens on erythrocytes. Methods: Sixteen persons with A blood group and anti-B antibody adsorbing ability (weak Bel, Bm and B3 antigens), 5 persons with B blood group and anti-A antibody adsorbing ability (weak Ax antigen) and 2 persons with O blood group and anti-B antibody adsorbing ability (weak Bel antigen) were investigated as the cases of type II-III of ABO discrepancy and weak B antigen. Liquid chromatography, agglutination, inhibition of agglutination and adsorption reactions at 4 °C and 37 °C with prolonged incubation (12 hours) were used in the study. Results: The persons with A blood group revealed by forward typing at 4 °C and O blood group detected by reverse typing at 37 °C showed the ability of the erythrocytes to adsorb anti-B antibody. The persons with B blood group revealed by forward typing with presence of anti-B antibodies reactive at 37 °C showed the ability of erythrocytes to adsorb anti-A antibody. Prolonged incubation at reverse typing, adsorption-elution tests, inhibition of haemagglutination and liquid chromatography were used to define blood group specificity. Conclusion: Prolonged incubation during reverse typing at 4 °C and 37 °C, adsorption at 4 °C, heat elution and liquid chromatography might help to detect blood group type in cases of type II-III of ABO discrepancy.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Resolving discrepancies in forward and reverse ABO blood group typing

Grigorovich,

Olexiyovich,

Solomonivna

et al. 2023

Scripta Medica

View full text Add to dashboard Cite

show abstract

“… 5 , 6 There were reports of RBC ABO antigen weakness in patients with cancer, however, ABO antigen weakness in those patients were due to excessive ABO antigen that affect ABO typing results, rather than weakness of antigens on RBCs themselves. 13 , 14 We sought to find whether specific type of cancer or history of anticancer therapy were related with decreased ABO antigen expression on RBC. Although ABO antigen weakness was found in patients with various types of cancers including thyroid, lung, stomach, and others, the proportion of each cancer type was similar to the incidence of each cancer type in the Korean population.…”

Section: Discussionmentioning

confidence: 99%

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Choi,

Kim,

Suh

et al. 2024

Blood Advances

View full text Add to dashboard Cite

The ABO antigen weakness is rarely observed in ABO typing for transfusion. Hematologic diseases and associated gene mutations have been suggested as potential causes of this phenomenon, yet the precise etiology has not been elucidated. Through ABO typing and genetic analysis data conducted over 7 years, we have reconfirmed the association between ABO antigen weakness and hematologic diseases, especially acute myeloid leukemia (odds ratio (OR) 2.55, 95% confidence interval (CI) 1.12-5.83) and myelodysplastic syndrome (OR 6.94, 95% CI 2.86-16.83), and discovered previously unidentified candidate genes, CEBPA (OR 43.70, 95% CI 18.12-105.40), NRAS (OR 3.37, 95% CI 1.46-7.79), U2AF1 (OR 8.12, 95% CI 2.86-23.03) and PTPN11 (OR 4.52, 95% CI 1.51-13.50), seemingly associated with this phenomenon. Among these, CEBPA double mutations displayed a significant association, with ABO antigen weakness being observed in 20 out of the 25 individuals (80.0%) possessing these mutations. From this study, new factors associated with ABO antigen weakness have been identified.

show abstract

“…11 Subramanian R. et al, concluded that rarely patient with carcinoma and lymphoma can develop excess serum blood group substances that can deactivate the typing antisera. 12 Joshi et al, reported a case of ovarian mucinous cystadenoma who presented with blood group discrepancy due to surplus secretion of A blood group substance. The disappearance of the discrepancy after the tumor resection proved their findings.…”

Section: Discussionmentioning

confidence: 99%

ABO discrepancy in pediatric lymphomas and solid organ tumors.

Saqlain

Mazher²,

Fateen³

et al. 2022

TPMJ

View full text Add to dashboard Cite

Objective: To determine the frequency of ABO discrepancies in pediatric patients of lymphoma and solid organ tumors and to categorize these discrepancies and their resolution. Study Design: Cross-sectional study. Setting: Department of Hematology & Transfusion Medicine, The University of Child Health Sciences & The Children’s Hospital, Lahore. Period: November 2020 to September 2021. Material & Methods: ABO blood group discrepancies were assessed by tube method of blood grouping, using antisera A, B, AB & D for forward grouping and A, B, and O cells for reverse grouping. Auto control was also run. The resolution techniques were used accordingly. The collected data was checked for its completeness, consistency and accuracy before analysis which was done on SPSS version 26. Results: In this study, a total of 105 subjects were included with mean age of 5.64 ±2.1 years. Among them 72(68.6%) were male and 33(31.4%) were female. Out of total samples processed, three (2.9%) discrepancies found, 1 in female and 2 in male patients. There were two cases of Group I ABO discrepancies, one of which was resolved by elution, antibody screening and identification and other by incubation at 37oC and correlation with previous transfusion history. One case of Group II ABO discrepancy which was resolved by incubation at 40C for 30 minutes. Conclusion: This shows that ABO discrepancies occur in pediatric patients of lymphoma and solid organ tumors. So, the interpretation of forward and reverse ABO blood grouping, identification and resolution of ABO discrepancies in these patients should be done very carefully to avoid any transfusion related adverse reactions.

show abstract

A closer look into blood group discrepancy arising due to an underlying malignancy

Cited by 5 publications

References 9 publications

Resolving discrepancies in forward and reverse ABO blood group typing

Resolving discrepancies in forward and reverse ABO blood group typing

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

ABO discrepancy in pediatric lymphomas and solid organ tumors.

Contact Info

Product

Resources

About